In this article by International Biopharmaceutical Industry, Martin Wing-King explores the demand for accelerated first-in-human trials and outlines how simple formulations can be leveraged for a faster way to progress through early clinical studies.
"Partners that understand the urgency of reaching clinical milestones under tight timelines by leveraging their extensive experience and specialized equipment are critical to the success of FiH trials."
By leveraging simplified formulation approaches such as capsules filled with API, drug developers can significantly expediate their path to the clinic. Strategic collaborations with experienced partners offering integrated drug development and manufacturing services can also streamline the process.
Continue reading the article here.
Credit:
International Biopharmaceutical Industry (IBI), Volume 7, Issue 3, September 2024, pages 14-16. © IBI Journal